Impact of timing of adjuvant chemotherapy initiation on survival for elderly patients with stage III colon cancer in Norway – a register-based cohort study

Standard treatment for stage III colon cancer is major surgical resection followed by adjuvant chemotherapy (ACT). Norwegian guidelines recommend initiation of ACT within 4–6 weeks after resection, but consensus regarding optimal timing of ACT is lacking. To investigate the impact of ACT timing on 5-year overall survival (OS) of elderly patients with stage III colon cancer in Norway. This population-based retrospective cohort study included patients aged 70 years or older who underwent major surgical resection for stage III colon cancer diagnosed between 2011 and 2021. Patients were grouped by ACT timing after resection: ≤ 6, 7–8, 9–10, and 11–13 weeks, in addition to those with resection only. The 5-year OS was assessed using Kaplan-Meier analysis and Cox proportional hazards models. Among 4 075 patients included, 1 408 were provided ACT. Median timing of ACT was 6.4 weeks after resection. Initiation of ACT in weeks 7–10 after resection was not associated with increased mortality risk compared to initiation within the first 6 weeks. Delaying the initiation of ACT beyond 10 weeks after resection was associated with worse 5-year OS (hazard ratio 1.49, 95% confidence interval 1.04–2.12). The association between survival benefit and ACT timing varied based on risk levels: For low risk patients, there was an association of improved survival benefit when ACT was initiated within 8 weeks after resection compared to resection alone, whereas for high risk patients, the association of survival benefit was better for those provided ACT in weeks 9–10 as well. Our findings support initiation of ACT within 8 weeks after major resection to maximise survival benefits in elderly patients with stage III colon cancer. However, for certain patient groups, initiation of ACT seems beneficial even up to 10 weeks after resection. The findings suggest greater flexibility in ACT initiation timing, benefiting both patients and health care services.

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2025-10-14
DOI
https://doi.org/10.1186/s12885-025-14942-y
Primary Topic
Colorectal Cancer Surgical Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of timing of adjuvant chemotherapy initiation on survival for elderly patients with stage III colon cancer in Norway – a register-based cohort study

Beate Hauglann, Elin Marthinussen Gustavsen, Eva Stensland, Yohannes Yebabe Tesfay et al.
BMC Cancer
Colorectal Cancer Surgical Treatments
article

Impact of timing of adjuvant chemotherapy initiation on survival for elderly patients with stage III colon cancer in Norway – a register-based cohort study

Beate Hauglann, Elin Marthinussen Gustavsen, Eva Stensland, Yohannes Yebabe Tesfay, Ellinor Haukland, Stig Norderval, Liv Marit Dørum
article en

Abstract

Standard treatment for stage III colon cancer is major surgical resection followed by adjuvant chemotherapy (ACT). Norwegian guidelines recommend initiation of ACT within 4–6 weeks after resection, but consensus regarding optimal timing of ACT is lacking. To investigate the impact of ACT timing on 5-year overall survival (OS) of elderly patients with stage III colon cancer in Norway. This population-based retrospective cohort study included patients aged 70 years or older who underwent major surgical resection for stage III colon cancer diagnosed between 2011 and 2021. Patients were grouped by ACT timing after resection: ≤ 6, 7–8, 9–10, and 11–13 weeks, in addition to those with resection only. The 5-year OS was assessed using Kaplan-Meier analysis and Cox proportional hazards models. Among 4 075 patients included, 1 408 were provided ACT. Median timing of ACT was 6.4 weeks after resection. Initiation of ACT in weeks 7–10 after resection was not associated with increased mortality risk compared to initiation within the first 6 weeks. Delaying the initiation of ACT beyond 10 weeks after resection was associated with worse 5-year OS (hazard ratio 1.49, 95% confidence interval 1.04–2.12). The association between survival benefit and ACT timing varied based on risk levels: For low risk patients, there was an association of improved survival benefit when ACT was initiated within 8 weeks after resection compared to resection alone, whereas for high risk patients, the association of survival benefit was better for those provided ACT in weeks 9–10 as well. Our findings support initiation of ACT within 8 weeks after major resection to maximise survival benefits in elderly patients with stage III colon cancer. However, for certain patient groups, initiation of ACT seems beneficial even up to 10 weeks after resection. The findings suggest greater flexibility in ACT initiation timing, benefiting both patients and health care services.

BMC CancerVol. 25(1)
University Hospital of North Norway (NO), Norwegian Institute of Public Health (NO), Nordland Hospital Trust (NO), Cancer Registry of Norway (NO), Northern Norway Regional Health Authority (NO), UiT The Arctic University of Norway (NO), University of Stavanger (NO)
Universitetet i Tromsø, Helse Nord RHF
Openalex Percentile: Top 61%
Colorectal Cancer Surgical Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.